Erudio Healtherudio.com
Drug
Loncastuximab tesirine trials: what clinicians said in public
An HCP commentary report on 1 clinical trial studying loncastuximab tesirine: LOTIS-9. It covers what clinicians said in public about one trial, on podcasts, videos and posts, every statement linked to its source. Below them, 4 more trials with public commentary and no report yet.
| Trial | Indication | Phase | Statements | Sources | Size | Checked | Preview |
|---|---|---|---|---|---|---|---|
| LOTIS-9 NCT05144009 · ADC Therapeutics S.A. | previously untreated unfit/frail diffuse large B-cell lymphoma | Phase 2 | 49 | 10 | Focused | Nov 22, 2026 | Preview |
| No report yetTrials with public commentary we haven't built a report for. Size is an estimate of the verified statements the commentary we've indexed so far will yield; final coverage is set when we build the report, within 24 hours of your confirmed order. You never pay more than quoted: a report delivered at a smaller size costs that size's price. Some can also be requested as a free preview. | |||||||
| LOTIS-2 NCT03589469 · ADC Therapeutics S.A. DeepView → | relapsed or refractory diffuse large B-cell lymphoma | Phase 2 | Deep | View | |||
| LOTIS-7 NCT04970901 · ADC Therapeutics S.A. DeepView → | relapsed or refractory B-cell non-Hodgkin lymphoma | Phase 1 | Deep | View | |||
| LOTIS-5 NCT04384484 · ADC Therapeutics S.A. StandardView → | relapsed or refractory diffuse large B-cell lymphoma | Phase 3 | Standard | View | |||
| LOTIS-3 NCT03684694 · ADC Therapeutics S.A. FocusedView → | advanced diffuse large B-cell or mantle cell lymphoma | Phase 1/Phase 2 | Focused | View | |||